Regulation and Clinical Significance of Urokinase-Receptor (u-PAR), an Invasion-Related Molecule

H. Allgayer

doi:10.1055/s-2006-926584

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2006; 44(6): 503-511
DOI: 10.1055/s-2006-926584

Übersicht

Regulation and Clinical Significance of Urokinase-Receptor (u-PAR), an Invasion-Related Molecule

Regulation und klinische Relevanz des invasionsassoziierten Moleküls Urokinaserezeptor (u-PAR)H. Allgayer¹

¹Department of Experimental Surgery and Molecular Oncology, Klinikum Mannheim, and Joint Unit Molecular Oncology of Solid Tumors - DKFZ (German Cancer Research Center) Heidelberg, Klinikum Mannheim, Mannheim

Abstract

Zusammenfassung

Dieser Artikel gibt einen Überblick über den Urokinase-Rezeptor (u-PAR), eines der wichtigsten Moleküle in der tumorassoziierten Proteolyse, Invasion und Metastasierung. Schwerpunkt dieser Zusammenfassung ist die Beschreibung der molekularen Regulation des u-PAR und seine potenzielle klinische und therapeutische Relevanz in gastrointestinalen Karzinomen.

Abstract

This review focuses on the urokinase-receptor (u-PAR), one of the critical molecules mediating tumor-associated proteolysis, invasion, and metastasis, amongst other phenomena associated with tumor progression. Especially, the article gives an overview on the molecular regulation of u-PAR, and its potential clinical and therapeutic relevance in gastrointestinal cancers.

Schlüsselwörter

U-PAR - Transkription - Regulation - gastrointestinales Karzinom

Key words

U-PAR - transcription regulation - colorectal cancer

Volltext

Referenzen

References

1 Hanahan D, Weinberg R A. The hallmarks of cancer. Cell. 2000; 100 57-70
2 Dvorak H F. Tumors: Wounds that do not heal. N Engl J Med. 1986; 315 1650-1659
3 Liotta L A. Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res. 1986; 46 1-7
4 Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis. 1992; 6 (Suppl 4) 3-26
5 Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis. 1988; 2 73-84
6 Blasi F. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. BioEssays. 1993; 15 105-111
7 Dano K, Andreasen P A, Grondahl-Hansen J. et al . Plasminogen-activators, tissue degradation, and cancer. Adv Cancer Res. 1985; 44 139-266
8 Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell. 1991; 64 327-336
9 Markus G. The relevance of plasminogen activators to neoplastic growth. Enzyme. 1988; 40 158-172
10 Andreasen P A, Sottrup-Jensen L, Kjoller L. et al . Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett. 1994; 338 239-245
11 Duffy M J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992; 10 145-155
12 Günzler W A, Steffens G J, Ötting F. et al . Structural relationship between human high and low molecular mass urokinase. Hoppe-Seyler’s J Physiol Chem. 1982; 363 133-141
13 Günzler W A, Steffens G J, Ötting F. et al . The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe-Seyler’s J Physiol Chem. 1982; 363 1155-1165
14 Wun T, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem. 1982; 257 7262-7268
15 Wun T C, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem. 1982; 257 3276-3283
16 Gronow M, Bliem R. Production of human plasminogen activators by cell culture. Trends Biotech. 1983; 1 26-29
17 Vassalli J D, Dayer J M, Wohlwend A. et al . Concomitant secretion of pro-urokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes/macrophages. J Exp Med. 1984; 159 1653-1668
18 Stoppelli M P, Tacchetti C, Cubellis M. et al . Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell. 1986; 45 675-684
19 Stoppelli M P, Corti A, Soffientini A. et al . Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA. 1985; 82 4939-4943
20 Olson D, Pollanen J, Hoyer-Hansen G. et al . Internalization of the urokinase-plasminogen activator type-1 complex is mediated by the urokinase receptor. J Biol Chem. 1992; 267 9129-9133
21 Cubellis M V, Wun T C, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990; 9 1079-1085
22 Conese M, Olson D, Blasi F AD. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and (2-macroglobulin receptor. J Biol Chem. 1994; 269 17 886-17 892
23 Nykjaer A, Petersen C M, Moller B. et al . Purified (2 macroglobulin receptor/LDL receptor related protein binds urokinase-plasminogen activator inhibitor type 1 complex. Evidence that the (2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992; 267 14 543-14 546
24 Nykjaer A, Kjoller L, Cohen R L. et al . Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2 macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem. 1994; 269 25 668-25 676
25 Nykjaer A, Kjoller L, Cohen R L. et al . Both pro-uPA and uPA:PAI-1 complex bind to the (2-macroglobulin receptor/LDL receptor-related protein. Evidence for multiple independent contacts between the ligands and receptor. Ann NY Acad Sci. 1994; 737 483-485
26 Behrendt N, Ronne E, Ploug M. et al . The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem. 1990; 265 6453-6460
27 Ploug M, Behrendt N, Lober D. et al . Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Sem Thromb Hem. 1991; 17 183-193
28 Estreicher A, Muhlhauser J, Carpentier J L. et al . The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990; 111 783-792
29 Moller L B. Structure and function of the urokinase receptor. Blood Coagulation and Fibrinolysis. 1993; 4 293-303
30 Moller L B, Ploug M, Blasi F. Structural requirements for glycosyl-phosphatidylinositol anchor attachment in the cellular receptor for urokinase plasminogen activator. Eur J Biochem. 1992; 208 493-500
31 Ploug M, Ronne E, Behrendt N. et al . Cellular receptor for urokinase-plasminogen activator: Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991; 266 1926-1933
32 Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. J Biol Chem. 1991; 266 12 752-12 758
33 Min H Y, Semnani R, Mizukami I F. et al . cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J Immunol. 1992; 148 3636-3642
34 Vassalli J D, Baccino D, Belin D. A cellular binding site for the Mr 55 000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985; 100 86-92
35 Plesner T, Ralfkiaer E, Wittrup M. et al . Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoetic tissue. Am J Clin Pathol. 1994; 102 835-841
36 Allgayer H, Heiss M M, Riesenberg R. et al . Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA-R and CK18: Investigation of sensitivity, specificity and reproducibility of an immunogold/alcaline phosphatase double-staining protocol. J Histochem Cytochem. 1997; 45 203-212
37 Langer D J, Kuo A, Kariko K. et al . Regulation of the endothelial cell urokinase-type plasminogen activator receptor - evidence for cyclic AMP-dependent and protein kinase C-dependent pathways. Circulation Research. 1993; 72 330-340
38 Romer J, Lund L R, Eriksen J. et al . The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. Invest Dermatol. 1994; 102 519-522
39 Sillaber C, Baghestanian M, Hofbauer R. et al . Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem. 1997; 272 7824-7832
40 May A E, Kanse S M, Lund L R. et al . Urokinase receptor (CD 87) regulates leukocyte recruitment via (2 integrins in vivo. J Exp Med. 1998; 188 1029-1037
41 Dewerchin M, Nuffelen A V, Wallays G. et al . Generation and characterization of urokinase receptor deficient mice. J Clin Invest. 1996; 97 870-878
42 Pedersen H, Grondahl-Hansen J, Francis D. et al . Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 1994; 54 120-123
43 Resnati M, Gutringer M, Valcamonica S. et al . Proteolytic cleavage of the urokinse receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996; 15 1572-1582
44 Xue W, Mizukami I, Todd R F IIIrd. et al . Urokinase-type plasminogen activator receptors associate with (1 and (3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res. 1997; 57 1682-1689
45 Wei Y, Waltz D A, Rao N. et al . Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994; 269 32 380-32 388
46 Wei Y, Lukashev M, Simon D I. et al . Regulation of integrin function by the urokinase receptor. Science. 1996; 273 1551-1555
47 Aguirre-Ghiso J A, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin-mediated adhesion and signaling. J Cell Biol. 1999; 144 1285-1294
48 Busso N, Masur S K, Lazega D. et al . Induction of cell migration by pro-urokinase to its receptor: Possible mechanism for signal transduction in human epithelial cells. J Cell Biol. 1994; 126 259-270
49 Tang H, Kerina D M, Hao Q. et al . The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem. 1998; 273 18 268-18 272
50 Stahl A, Mueller B M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol. 1995; 129 335-344
51 Pöllänen M, Hedman K, Nielsen L S. et al . Ultrastructural localization of plasma-membrane associated urokinase-type plasminogen activator at focal contacts. Cell Biol. 1988; 106 87-95
52 Del R osso M, Anichini E, Pedersen N. et al . Urokinase-urokinase receptor interaction: Non-mitogenic signal transduction in human epidermal cells. Biochem Biophys Res Commun. 1993; 190 347-352
53 Konakova M, Hucho F, Schleunig W D. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem. 1998; 253 421-429
54 Bohuslav J, Horejsi V, Hansmann C. et al . Urokinase plasminogen activator receptor, (2-integrins, and Src kinases within a single receptor complex of human monocytes. J Exp Med. 1995; 181 1381-1390
55 Jankun J, Merrick H W, Goldblatt P J. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem. 1993; 53 135-144
56 Sier C FM, Vespaget H W, Griffionen G. et al . Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut. 1993; 34 80-85
57 Pyke C, Kristensen P, Ralfkiaer E. et al . The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 1991; 51 4067-4071
58 Pyke C, Kristensen P, Ralfkiaer E. et al . Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991; 138 1059-1067
59 Heiss M M, Babic R, Allgayer H. et al . Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol. 1995; 13 2084-2093
60 Heiss M M, Babic R, Allgayer H. et al . The prognostic impact of the urokinase-type plasminogen activator system is associated with tumor differentiation in gastric cancer. Eur J Surg Onc. 1996; 22 74-77
61 Cantero D, Friess H, Deflorin J. et al . Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Brit J Cancer. 1997; 75 388-395
62 Romer J, Pyke C, Lund L. et al . Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer. 1994; 57 553-560
63 Morita S, Sato A, Hayakawa H. et al . Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor, and inhibitors in human non-small cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization. Int J Cancer. 1998; 78 286-292
64 Wang H, Skibber J, Juarez J. et al . Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer. 1994; 58 650-657
65 Bianchi E, Cohen R L, Thor A T III. et al . The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 1994; 54 861-866
66 Hollas W, Blasi F, Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res. 1991; 51 3690-3695
67 Sliutz G, Eder H, Koelbl H. et al . Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR. Breast Cancer Res Treat. 1996; 40 257-263
68 Kariko K, Kuo A, Boyd D. et al . Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res. 1993; 53 3109-3117
69 Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: The role of cell surface-bound urokinase. J Cell Biol. 1988; 107 2427-2445
70 Kook Y H, Adamski J, Zelent A. et al . The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 1994; 13 3983-3991
71 Quattrone A, Fibbi G, Anichini E. et al . Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res. 1995; 55 90-95
72 Mohanam S, Sawaya R, McCutcheon I. et al . Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993; 53 4143-4147
73 Liu G, Shuman M A, Cohen R L. Co-expression of urokinase, urokinase receptor and PAI 1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 1995; 60 501-506
74 Kim J, Yu W, Kovalski K. et al . Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 1998; 94 353-362
75 Min H Y, Doyle L V, Vitt C R. et al . Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996; 56 2428-2433
76 Schlechte W, Murano G, Boyd D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res. 1989; 49 6064-6069
77 Reiter L S, Kruithof E KO, Cajot J F. et al . The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int J Cancer. 1993; 53 444-450
78 Schmalfeldt B, Kuhn W, Reuning U. et al . Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 1995; 55 3958-3963
79 Jänicke F, Schmitt M, Pache L. et al . Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res and Treatment. 1993; 24 195-208
80 Heiss M M, Allgayer H, Gruetzner K U. et al . Individual development and uPA-receptor-expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer. Nature Medicine. 1995; 1 1035-1039
81 Duffy M J, Reilly D, O’Sullivan C. et al . Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990; 50 6827-6829
82 Mulcahy H E, Duffy M J, Gibbons D. et al . Urokinase-type plasminogen activator and outcome in Dukes‘ B colorectal cancer. Lancet. 1994; 344 583-584
83 Ganesh S, Sier C FM, Heerding M M. et al . Urokinase receptor and colorectal cancer survival. Lancet. 1994; 344 401-402
84 Nekarda H, Schmitt M, Ulm K. et al . Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994; 54 2900-2907
85 Heiss M M, Allgayer H, Gruetzner K U. et al . Clinical value of an extended biological staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg. 1997; 226 736-744
86 Allgayer H, Heiss M M, Schildberg F W. Prognostic factors in gastric cancer: A review. Brit J Surgery. 1997; 84 1651-1664
87 Allgayer H, Babic R, Grützner K U. et al . Tumor-associated proteases and inhibitors in gastric cancer: Analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis. 1998; 16 62-73
88 Nekarda H, Schlegel P, Schmitt M. et al . Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res. 1998; 4 1755-1763
89 Osborne M P, Rosen P P. Detection and management of bone marrow micrometastases in breast cancer. Oncology. 1994; 8 25-31
90 Riethmueller G, Johnson J. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr Opin Immunol. 1992; 4 647-655
91 Schlimok G, Funke I, Bock B. et al . Epithelial tumor cells in bone marrow of patients with colorectal cancer: Immunocytochemical detection, phenotypic characterization, and prognostic significance. J Clin Oncol. 1990; 8 831-837
92 Allgayer H, Heiss M M, Riesenberg R. et al . Urokinase plasminogen activator receptor (uPA-R) - a potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Research. 1997; 57 1394-1399
93 Heiss M M, Simon E H, Beyer B CM. et al . Minimal residual disease in gastric cancer: First evidence of an independent prognostic relevance or urokinase receptor gene expression by disseminated tumor cells in a large series of patients. J Clin Oncology. 2002; 20 2005-2016
94 Harbeck N, Kates R, Look M P. et al . Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1 (n = 3,424). Cancer Res. 2002; 62 4617-1622
95 Cavallaro U, DelVecchio A, Lappi D A. et al . A conjugate between human urokinase and saporin, a type-1-ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem. 1993; 68 23 186-23 190
96 Lengyel E, Wang H, Stepp E. et al . Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem. 1996; 271 23 176-23 184
97 Gum R, Juarez J, Allgayer H. et al . Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires a JNK1-dependent signaling module. Oncogene. 1998; 17 213-225
98 Shetty S, Kumar A, Idell S. Posttranscriptional regulation of urokinase receptor mRNA: Identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol. 1997; 17 1075-1083
99 Lund L R, Ellis V, Ronne E. et al . Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549. Biochem J. 1995; 310 345-352
100 Nykjaer A, Conese M, Cremona O. et al . Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 1997; 16 2610-2620
101 Wagner S N, Atkinson M J, Thanner S. et al . Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol. 1995; 147 183-192
102 Borglum A D, Byskov A, Ragno P. et al . Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. Am J Hum Genet. 1992; 50 492-497
103 Roldan A, Cubellis M, Masucci M. et al . Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in plasmin-dependent proteolysis. EMBO J. 1990; 9 467-474
104 Pyke C, Eriksen J, Solberg H. et al . An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS. 1993; 326 69-74
105 Soravia E, Grebe A, De Luca P. et al . A conserved TATA-less proximal promoter drives basal transcription from the urokinase-plasminogen activator receptor gene. Blood. 1995; 86 624-635
106 Means A L, Farnham P J. Transcription initiation from the dihydrofolate reductase promoter is positioned by HIP1 binding at the initiation site. Mol Cell Biol. 1990; 10 653-661
107 Suh T, Nerlov K, Dano K. et al . The murine urokinase-type plasminogen activator receptor gene. J Biol Chem. 1994; 269 25 992-25 998
108 Lengyel E, Wang H, Gum R. et al . Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene. 1997; 14 2563-2573
109 Allgayer H, Wang H, Wang Y. et al . Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator-protein-2(-related factor. J Biol Chem. 1999; 274 4702-4714
110 Boyd D. Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. Cancer Res. 1989; 49 2427-2432
111 Mandriota S J, Seghezzi G, Vassalli J D. et al . Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem. 1995; 270 9709-9716
112 Ando Y, Jensen P J. Protein kinase C mediates upregulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro. J Cell Physiol. 1996; 167 500-511
113 Li C, Liu J N, Gurewich V. Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction. J Biol Chem. 1995; 270 30 282-30 285
114 Muller S M, Okan E, Jones P. Regulation of urokinase receptor transcription by Ras- and Rho-family GTPhases. Biochem Biophys Res Commun. 2000; 270 892-898
115 Okan E, Drewett V, Shaw P E. et al . The small-GTPase Ra1A activates transcription of the urokinase plasminogen activator receptor (u-PAR) gene via an AP1-dependent mechanism. Oncogene. 2001; 15 1816-1824
116 Allgayer H, Wang H, Shirasawa S. et al . Targeted Disruption of K-ras oncogene in an invasive cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer. 1999; 80 1884-1891
117 Allgayer H, Boyd D D, Heiss M M. et al . Elevated Src kinase activity in primary colorectal cancer is a biological indicator of poor clinical prognosis. Cancer. 2002; 94 344-351
118 Boyd D D, Wang H, Avila H. et al . Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin Cancer Res. 2004; 10 1545-1555
119 Wang Y, Dang J, Wang H. et al . Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem. 2000; 267 3248-3254
120 Wang H, Yang L, Jamaluddin M S. et al . The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. J Biol Chem. 2004; 279 22 674-22 683
121 Hapke S, Gawaz M, Dehne K. et al . ß3A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA2/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol. 2001; 6 2118-2132
122 Cmarik J L, Min H, Hegamyer G. et al . Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA. 1999; 96 14 037-14 042
123 Hsu T C, Young M R, Cmarik J. et al . Activator protein 1 (AP-1) and nuclear factor kappaB-dependent transcriptional events in carcinogenesis. Free Radic Biol Med. 2000; 28 1338-1348
124 Leupold J H, Colburn, NH. et al . First evidence for the new tumor suppressor Pdcd4 as a regulator of u-PAR, an invasion-related gene. Proc Am Assoc Cancer Res. 2002; 43 622
125 Wang H, Hicks J, Khanbolooki P. et al . Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene. Am J Pathol. 2003; 163 453-464
126 Schewe D, Heiss M M, Boyd D D. et al . Transcription factor binding to region - 152/- 135 of the urokinase receptor (u-PAR) gene. First analysis of a clinical relevance in gastrointestinal carcinomas. Proc Am Assoc Cancer Res. 2001; 42 618
127 Allgayer H, Wang H, Gallick G E. et al . Transcriptional induction of the urokinase-receptor (u-PAR) gene by a constitutively active Src: Requirement of an upstream motif (- 152/- 135) bound with Sp1. J Biol Chem. 1999; 274 18 428-18 437
128 Renatus M, Bode W, Huber R. et al . Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. J Med Chem. 1998; 31/41 5445-5456
129 Mignatti P, Mazzieri R, Rifkin D B. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol. 1991; 113 1193-1201
130 Wilhelm O, Weidle U, Höhl S. et al . Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett. 1994; 337 131-134
131 Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumour metastasis. Cell. 1963; 35 611-619
132 Llinas P, Le Du MH, Gardsvoll H. et al . Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005; 24 1655-1663

Prof. Dr. med. Heike Allgayer, MD, PhD

Department of Experimental Surgery, Joint Unit Molecular Oncology of Solid Tumors - DKFZ (German Cancer Research Center) Heidelberg, Klinikum Mannheim, Ruprecht-Karls-Universität Heidelberg

Theodor Kutzer Ufer 1 - 3

68135 Mannheim

Telefon: ++ 49/6 21/3 83 41 83

Fax: ++ 49/6 21/3 83 38 09

eMail: heike.allgayer@chir.ma.uni-heidelberg.de